A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 2, 2006, Pages 367-371

  Santagostino, Elena ^a   Mancuso, M E ^a   Rocino, A ^b   Mancuso, G ^c   Scaraggi, F ^d   Mannucci, P M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b San Giovanni Bosco Hospital   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d POLICLINICO   (Italy)

Author keywords

Anti FVIII inhibitors; Hemophilia; Joint bleeding; rFVIIa

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEADACHE; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HOME CARE; HUMAN; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VASCULAR ACCESS; VISUAL ANALOG SCALE; DRUG ANTAGONISM; INFANT; MALE; MIDDLE AGED; PRESCHOOL CHILD; SAFETY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; FACTOR VIIA; HEMARTHROSIS; HEMOPHILIA A; HUMANS; INFANT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SAFETY;

EID: 33645573977     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01772.x     Document Type: Article

References (12)

1. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in hemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
2. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention. Br J Haematol 1999:104: 22-6.
3. van't Veer C, Golden N, Mann K. Inhibition of thrombin generation by the zymogen factor VII: Implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-5.
4. Hoffman M, Monroe III DM, Roberts HR. Activated factor VII activates factor IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9: S61-5.
5. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923-30.
6. Butenas S, Brummel KE, Bouchard BA, Mann KG. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 1: 1158-60.
7. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 7: 517-22.
8. O'Connell N, Chen J, Byrne M, O'Shea E, Smyth H, Smith OP. Massive pseudotumor resection with recombinant factor VIIa (NovoSeven) cover. Br J Haematol 2002; 116: 645-8.
9. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven ®). J Thromb Haemost 2003; 1: 450-5.
10. Parameswaran R, Shapiro AD, Gill JC, Kessler CM, HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
11. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
12. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.